Quinoa to improve blood sugar control and lipids in early type 2 diabetes
Quinoa Improves Glycolipid Metabolism and Glucose Fluctuation Based on β-Cell Function in Early-stage Type 2 Diabetes
NA · Qilu Hospital of Shandong University · NCT07329231
This trial will try a quinoa-based diet to see if it improves blood sugar levels, reduces glucose swings, and helps lipid and insulin measures in adults with early-stage type 2 diabetes.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 20 Years to 70 Years |
| Sex | All |
| Sponsor | Qilu Hospital of Shandong University (other) |
| Locations | 1 site (Jinan, Shandong) |
| Trial ID | NCT07329231 on ClinicalTrials.gov |
What this trial studies
Adults with early-stage type 2 diabetes (diagnosis <5 years, HbA1c 6.5%–10%, no prior insulin) are assigned to a quinoa-based dietary intervention that replaces traditional starchy foods and compared with a usual-diet control. The study tracks fasting and postprandial glucose, HbA1c, lipid panels, continuous glucose metrics (time in range/time above range), and measures of β-cell function and insulin resistance (HOMA-β, HOMA-IR). Outcomes will also include changes in oral hypoglycemic medication use. The intervention is delivered at a single center with regular follow-up visits for metabolic testing and dietary support.
Who should consider this trial
Good fit: Adults aged 20–70 with early-stage T2DM diagnosed by 1999 WHO criteria, disease duration under 5 years, HbA1c 6.5%–10%, no history of insulin therapy, and no major acute or chronic exclusionary conditions are ideal candidates.
Not a fit: People with long-standing or insulin-dependent diabetes, major organ disease, pregnancy or planning pregnancy, quinoa/legume allergy, recent gastrointestinal illness, or active participation in other dietary/drug trials are unlikely to benefit from this intervention.
Why it matters
Potential benefit: If successful, a quinoa-based diet could improve blood glucose and lipid control, reduce glucose variability, support β-cell function, and potentially lower the need for medications.
How similar studies have performed: Small trials and observational studies of whole grains and quinoa-like grains suggest modest improvements in glycaemic and lipid markers, but large randomized trials specifically on quinoa are limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: patients diagnosed according to the 1999 WHO diagnostic criteria for T2DM with a duration of less than 5 years HbA1c levels between 6.5% and 10% no history of insulin therapy age between 20 and 70 years. Exclusion Criteria： acute complications of diabetes, such as diabetic ketoacidosis severe acute or chronic conditions affecting the liver, kidneys, heart, cerebrovascular system, gastrointestinal tract, or acute infectious diseases pregnancy or plans for pregnancy soon allergies to quinoa or bean products participation in other dietary interventions or drug clinical trials within the past three months gastrointestinal diseases within two weeks prior to enrolment.
Where this trial is running
Jinan, Shandong
- Qilu Hospital of Shandong University — Jinan, Shandong, China (RECRUITING)
Study contacts
- Study coordinator: Xiao K Tang
- Email: tangkx_ql@hotmail.com
- Phone: 008618560083053
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Type 2 Diabetes Mellitus, Diabetes Mellitus, Quinoa Dietary Intervention, Glycaemic Fluctuations, Glycolipid metabolism